Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Open Access
- 28 February 2013
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 15 (3), 203-211
- https://doi.org/10.1038/gim.2012.119
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast CancerJournal of Clinical Oncology, 2012
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Breast Cancer Research and Treatment, 2011
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast CancerThe Oncologist, 2010
- Breast Cancer Multidisciplinary Team Adjuvant Therapy Decision Making and Adjuvant! OnlineClinical Oncology, 2010
- Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?The American Journal of Surgery, 2008
- Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare DataValue in Health, 2008
- Impact of gene expression profiling tests on breast cancer outcomes.Evidence Report/Technology Assessment, 2008
- Patient Time Costs Associated With Cancer CareJNCI Journal of the National Cancer Institute, 2007
- Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?Genetics in Medicine, 2005
- Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.2005